Focus on the Role of D-serine and D-amino Acid Oxidase in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS) by Kondori, N R et al.
MINI REVIEW
published: 13 February 2018
doi: 10.3389/fmolb.2018.00008
Frontiers in Molecular Biosciences | www.frontiersin.org 1 February 2018 | Volume 5 | Article 8
Edited by:
Jumpei Sasabe,
Keio University, Japan
Reviewed by:
Elena Rosini,
University of Insubria, Italy
Doriano Lamba,
Consiglio Nazionale Delle Ricerche
(CNR), Italy
*Correspondence:
Jacqueline S. de Belleroche
j.belleroche@imperial.ac.uk
†
These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Structural Biology,
a section of the journal
Frontiers in Molecular Biosciences
Received: 29 November 2017
Accepted: 19 January 2018
Published: 13 February 2018
Citation:
Kondori NR, Paul P, Robbins JP, Liu K,
Hildyard JCW, Wells DJ and de
Belleroche JS (2018) Focus on the
Role of D-serine and D-amino Acid
Oxidase in Amyotrophic Lateral
Sclerosis/Motor Neuron Disease
(ALS). Front. Mol. Biosci. 5:8.
doi: 10.3389/fmolb.2018.00008
Focus on the Role of D-serine and
D-amino Acid Oxidase in
Amyotrophic Lateral Sclerosis/Motor
Neuron Disease (ALS)
Nazanin R. Kondori 1,2, Praveen Paul 1, Jacqueline P. Robbins 1, Ke Liu 2,
John C. W. Hildyard 2, Dominic J. Wells 2† and Jacqueline S. de Belleroche 1*†
1Neurogenetics Group, Division of Brain Sciences, Department of Medicine, Imperial College London, London,
United Kingdom, 2Neuromuscular Diseases Group, Department of Comparative Biomedical Sciences, Royal Veterinary
College, London, United Kingdom
We have investigated a pathogenic mutation in D-amino acid oxidase (DAO), DAOR199W,
associated with familial Amyotrophic Lateral Sclerosis (ALS) that impairs D-serine
metabolism and causes protein aggregation, autophagy and cell death in motor neuron
cell lines. These features are consistent with the pathogenic processes occurring in
ALS but most importantly, we have demonstrated that activation of the formation of
ubiquitinated protein inclusions, increased autophagosome production and apoptotic cell
death caused by the mutation in cell lines are attenuated by 5,7-dichlorokynurenic acid
(DCKA), a selective inhibitor of the glycine/D-serine binding site of the NMDA receptor.
D-serine is an essential co-agonist at this glutamate receptor. This data provides insight
into potential upstream mechanisms that involve the action of D-serine at the NMDA
receptor and might contribute to neurodegeneration. This is highly relevant to sporadic
ALS (SALS), familial ALS, as well as ALS models, where elevated levels of D-serine
have been reported and hence has broader clinical therapeutic implications. In order to
investigate this further, we have generated a transgenic line expressing the pathogenic
mutation, in order to determine whether mice expressing DAOR199W develop a motor
phenotype and whether crossing the SOD1G93A model of ALS with mice expressing
DAOR199W affects disease progression. We found that heterozygous expression of
DAOR199W led to a significant loss of spinal cord motor neurons at 14 months, which
is similar to that found in homozygous mice expressing DAOG181R. We hypothesize that
DAO has potential for development as a therapeutic agent in ALS.
Keywords: Amyotrophic lateral sclerosis, motor neurons, D-amino acid oxidase, survival study, motor phenotype,
motor neuron degeneration, excitotoxicity, NMDA receptors
INTRODUCTION
The focus of this mini-review is to make the case for the potential involvement of D-serine in
neurodegenerative diseases which involves impaired activity of D-amino acid oxidase (DAO), the
enzyme responsible for its degradation, and is most strongly indicated in Amyotrophic lateral
Sclerosis ALS (ALS). On the other hand, we propose that in brain regions such as cerebral cortex,
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where levels of DAO are very limited, another mechanismmay be
involved which is mediated through the up-regulation of serine
racemase (SR), the biosynthetic enzyme responsible for D-serine
biosynthesis. Both mechanisms result in an upregulation of D-
serine caused either by impaired metabolism of D-serine by DAO
or increased biosynthesis by SR.
Background
Amyotrophic Lateral Sclerosis (ALS), the most common adult-
onset neuromuscular disease, is a highly debilitating, rapidly
progressing condition that causes muscle atrophy, paralysis,
impaired speech and swallowing, with death usually occurring
within 3–5 years of diagnosis. These clinical features reflect the
fundamental changes that occur in themotor neuron populations
of the spinal cord, brain stem and motor cortex that mediate
these essential motor functions. The typical neuropathological
features of ALS are characterized by the accumulation of cytosolic
ubiquitinated protein inclusions, most of which are positive for
TDP-43, encoded by TAR DNA binding protein 43 (TARDBP)
(Neumann et al., 2006). To-date, no effective treatments have
been discovered and new therapeutic approaches are urgently
needed.
Identification of mutations in the familial form of the disease
(FALS), which accounts for about 10% of ALS cases, has led
the way in the elucidation of disease mechanisms in both
the sporadic form and familial forms of the disease. To date,
mutations have been identified in approximately 70% of FALS
kindred, with the most common FALS genes being C9orf72,
Superoxide dismutase-1 (SOD1), TARDBP and Fused in Sarcoma
(FUS). Most importantly, it has emerged that the majority of
pathogenic mutations in FALS occur in genes encoding proteins
involved in RNA processing and proteostasis, covering protein
folding, the unfolded protein response involved in removal
of damaged/mutant proteins, protein trafficking and protein
degradation through proteasomal and autophagic pathways, all
of which play a fundamental role in normal motor neuron
function (Chen and de Belleroche, 2012). Studies on the effects
of these mutations associated with FALS has provided enormous
insight into the molecular mechanisms of disease which provides
a valuable framework of targets for potential drug development
(Taylor et al., 2016).
We recently reported a coding mutation inDAO (DAOR199W)
associated with FALS, lacking all previously identified mutations
(Mitchell et al., 2010). Interestingly, this mutation provides
a novel input into disease mechanisms, as it provides an
“upstream” trigger that may potentiate cell death in vulnerable
motor neurons. This will be the main focus of this mini review.
It has only relatively recently been established that D-amino
acids such as D-serine, D-alanine, and D-proline are found in
man, present in multiple tissues including the brain and spinal
cord. Of particular importance, D-serine is known to play a
crucial role in synaptic plasticity, where D-serine is thought to
be the major co-agonist at the NMDA receptor mediating Long
Term Potentiation (LTP) (Mothet et al., 2000, 2005; Yang et al.,
2003; Panatier et al., 2006; Li et al., 2013). Detailed analysis of the
crystal structure of human DAO has highlighted the structural
basis for marked differences seen in the properties of the human
protein compared to porcine DAO, with which it shares 85%
sequence identity, e.g., weaker binding to FAD and a slower rate
of Flavin reduction, and has established that these effects are due
to a hydrophobic stretch of amino acids (VAAGL) that lie at the
si-face that exists in a different conformation (Kawazoe et al.,
2006).
It has been established that D-serine is derived from L-serine
through the enzyme serine racemase (SR) (Wolosker et al.,
1999) (Figure 1A). This reaction is known to occur mainly in
neuronal cells, while L-serine is synthesized in astrocytes from
3-phosphoglycerate and is actively shuttled to neurons through
the transporters, such as ASCT1. Mammalian SR has a type
II beta eliminase fold and the enzyme catalyses both the beta
elimination of L-serine and its racemization to D-serine, the
mechanism of which has been further elucidated in recent human
SR structure/activity relationship studies (Nelson et al., 2017).
Levels of synaptic D-serine and L-serine are regulated
predominantly by three transporters, the Na+-independent
alanine-serine-cysteine 1 transporter (Asc-1) which is a high
affinity neuronal transporter selective for D- and L- amino
acids, the Na+-dependent alanine-serine-cysteine-threonine 2
transporter (ASCT2) with higher affinity for L-amino acids
than D-amino acids and alanine-serine-cysteine-threonine 1
transporter (ASCT1) which has a high affinity for small neutral
L amino acids. Studies on the effects of the G93ASOD1 mutation
on the activity of these transporters in a motor neuron cell line,
NSC-34, showed that D-serine uptake was significantly impaired
by the mutation, where the KM for D-serine was increased but no
change occurred in Vmax (Lee et al., 2017). In contrast, L-serine
uptake was increased. Both effects were Na+ dependent and small
interfering RNA studies showed that both ASCT2 (SLC1A5) and
ASCT1 (SLC1A4) mediated these effects.
Why Is DAO Relevant to a
Neurodegenerative Condition?
The finding of a mutation in DAO, which is transmitted with
disease offered the opportunity to elucidate pathogenic disease
mechanisms caused by the mutation. Indeed, both D-serine
and DAO, are strongly expressed in spinal cord and brain
stem (Horiike et al., 1994; Mitchell et al., 2010; Paul et al.,
2014), regions involved in ALS pathogenesis (Figures 1B,C,
respectively). Furthermore DAO enzyme activity is substantially
impaired by the presence of the mutation in spinal cord from a
case expressing this mutation compared to control tissue and also
in cell lines expressing DAOR199W compared to those expressing
DAOWT (Mitchell et al., 2010; Paul and de Belleroche, 2012;
Paul et al., 2014). Most importantly, D-serine has been shown
to be elevated in spinal cord, not only in sporadic cases of ALS
but also in the SOD1G93A mouse model of ALS (Sasabe et al.,
2007).
The functional effects of the presence of DAOR199W were
extensively investigated using a motor neuron cell line, NSC-
34, in order to determine whether the mutation influenced
proteostasis and cell viability (Figure 2A). Furthermore,
expression of DAOR199W caused increased ubiquitinated protein
aggregate formation (Figure 2B), which was associated with
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FIGURE 1 | Relevance of D-serine and D-amino acid oxidase (DAO) to ALS. (A) D-serine is synthesized from L-serine by serine racemase and is metabolized by DAO.
D-serine is a co-agonist with glutamate at the NMDA receptor (NMDAR). (B) D-serine in spinal cord motor neurons. Localisation of D-serine immunoreactivity in
mouse lumbar spinal cord. D-serine immunoreactivity is widespread in gray matter including motor neurons (arrowheads). Scale bar is 50µm. Data is taken from Paul
and de Belleroche (2012) with permission from Springer. (C) DAO-IR in human spinal cord. DAO is highly concentrated in motor neurons in spinal cord and brain stem
which are depleted in ALS. Distribution of DAO in lumbar spinal cord. Lumbar sections (L5) from control and amyotrophic lateral sclerosis (ALS) cases were stained for
DAO. Scale bar is 100 µm. Data taken from Paul et al. (2014) with permission from Elsevier.
significantly increased formation of autophagosomes compared
to DAOWT (Figure 2Ci), and increased levels of LC3-II, a
key marker of increased autophagy (Figure 2Cii). This effect
was significantly attenuated by the selective D-serine/glycine
site antagonist, 5,7-dichloro-4-hydroxyquinoline-2-carboxylic
acid (DCKA) (Figure 2Ciii), determined by Western blot
analysis (Figure 2Civ). Effects on cell viability were analyzed by
measurement of Annexin V, using Flow cytometry, and showed
a significant activation of apoptosis in the mutant cell line
compared to controls (Figure 2D; Paul et al., 2014). These results
demonstrated significant effects of the mutation to promote
aggregate formation, with increased autophagy and apoptosis, all
of which are consistent with neuropathological features found in
ALS cases.
Structure-function relationships have been studied in
human DAO mutations associated with ALS and other coding
substitutions by Cappelletti et al. (2015) and have provided
valuable information about the effects of these mutations.
The DAOR199W substitution altered protein conformation and
enzyme activity was lost, which resulted in an abnormal increase
in cellular D-serine levels, which could contribute to the protein
instability and decrease in kinetic efficiency seen in ALS and
potentially lead to increased synaptic D-serine. Reduced enzyme
activity has also been reported in spinal cord from an ALS
case harboring this mutation (Mitchell et al., 2010), Additional
studies on the human DAOG183R mutation that corresponds to
the G181R substitution found in a strain of ddY mice lacking
DAO activity also alters protein conformation and negatively
affects the ability of the apoprotein to bind to the flavin cofactor
in the orientation required for hydride-transfer during catalysis.
At the cellular level, the overexpressed DAOG183R was not fully
targeted to peroxisomes, formed protein aggregates colocalised
with ubiquitin, and significantly increased both the cellular
concentration of D-serine and the D/(D+L)-serine ratio. As
pointed out by Murtas et al. (2017), while both the DAOR199W
mutation associated with ALS and the DAOG331V variant related
to schizophrenia susceptibility led to the formation of protein
aggregates and apoptosis, DAOG183R over-expression did not
induce apoptosis.
The next conundrum to solve was to determine whether the
impaired level of DAO activity contributed to the pathogenic
process through reduced metabolism of D-serine and hence
build-up of D-serine, which could regulate the activity of
glutamate at the NMDA receptor and hence potentiate
excitotoxicity and cell death. Alternatively, the presence of
the mutant protein alone could be responsible for activating
apoptosis, without requiring the action of extracellular D-serine
at the NMDA receptor. In order to explore this mechanism,
we used a co-culture technique in which cells expressing
DAOR199W were placed in a trans-well above NSC-34 cells
separated by a membrane (0.4mm filter), in order to determine
whether an extracellular factor released from cells expressing
DAOR199W and not DAOWT or control cells would influence
survival. Interestingly, we found that apoptosis was sensitive to
attenuation by 5,7-dichlorokynurenic acid (DCKA), a selective
inhibitor of the glycine/D-serine binding site of the NMDA
receptor (Figure 2Ciii; Paul et al., 2014). Thus, this data
provided insight into upstream mechanisms that involve the
release of D-serine from neuronal and glial cells and lead to
neurodegeneration, which is mediated by the NMDA receptor.
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FIGURE 2 | Pathogenic processes caused by FALS-associated mutation DAOR199W. (A) Model showing the potential effects of DAOR199W. (B) Effect of DAOR199W
on ubiquitin aggregates. NSC-34 cells expressing GFP-tagged DAO 72h after transfection. Ubiquitin (UBQ) staining (red) with aggregates in GFP-positive cells are
shown in a merged image with DAPI nuclear staining. Data taken from Mitchell et al. (2010). (C) DAOR199W promotes autophagy. (i) NSC-34 cells were
co-transfected with RFP-tagged D-amino acid oxidase (DAO) and GFP-tagged protein light chain 3 (LC3). The number of vector or DAO transfected cells containing
more than 10 GFP-LC3 puncta or autophagosomes were quantified. (ii) Quantification of LC3 (I and II) using Western blot analysis. Rapamycin induced autophagy
was used as a positive control. Levels of LC3-II protein were calculated using densitometry and normalized to protein levels of RFP-vector. (iii) NSC-34 cells were
treated with 5,7-dichloro-4-hydroxyquinoline-2-carboxylic acid (DCKA), immunoblotted and quantified. Significant 1-way ANOVA with Friedman’s test subject to post
hoc testing with Dunn’s multiple comparison test or 2-way analysis of variance (ANOVA). Values are means ±SEM for 4–6 experiments, for p values, *p < 0.05; **p <
0.01; ***p < 0.001. The images shows RFP-DAO (red), ubiquitin (green), and DAPI nuclear stain (blue). DAPI, 4′,6-diamidino-2-phenylindole. Data taken from Paul
et al. (2014) with permission from Elsevier. (iv) A representative western blot is shown. (D) DAOR199W promotes apoptosis in neuronal cells. Annexin V levels in
NSC-34 neuronal cells co-cultured with C6 glial cells permanently expressing wild-type (WT) or DAOR199W, treated with vector or
5,7-dichloro-4-hydroxyquinoline-2-carboxylic acid (DCKA). Paired t-test used. Values are means ± standard error of the mean, for 3 experiments with p-values
shown, *p < 0.05, **p < 0.01. Data taken from Paul et al. (2014) with permission from Elsevier.
Is Motor Neuron Function Affected by
Impaired DAO Activity?
Characterisation of the effects of the in vivo expression of
an ALS-linked mutation in DAO on phenotype and loss of
spinal cord motor neurons was carried out using DAOR199W
transgenic mouse lines overexpressing DAOR199W, created using
human DAOR199W, driven by a chicken β-actin promoter
and cytomegalovirus enhancer. The DAOR199W transgene was
present in spinal cord and cerebral cortex at concentrations that
were 40-fold greater than those of mouse DAO, determined
by qPCR using human and mouse specific primers (Kondori
et al., 2017). DAO protein was found to be widely expressed
in heart, muscle, brain and spinal cord. Immuno-histochemical
staining of DAO in DAOR199W transgenic mice showed evidence
of increased ubiquitin staining compared to wild-type mice
(Kondori et al., 2017).
The development of ALS related disabilities were assessed in
both hind legs twice weekly for each mouse from approximately
30 days of age in DAOR199W transgenic mice. Neurological scores
were assigned using a scale of 0–4, established by the ALSTDI
through detailed observations of SOD1G93A mouse pathology
(Scott et al., 2008; Gill et al., 2009; Lincecum et al., 2010), where
0 was the full extension of hind legs and 4 indicated the inability
to right itself within 20 s. Body weight, motor features and gait
were monitored in a large cohort for one year blind to genotype
(Kondori et al., 2017) as previously described (Vincelette et al.,
2007; Sharp et al., 2008; Kaneb et al., 2011).
A distinct feature seen in DAOR199W mice, which are
heterozygous for the mutation, was kyphosis, a dorsal curvature
of the spine due to progressive rigid thoracolumbar kyphosis,
caused by a loss of muscle tone, secondary to motor neuron
degeneration. This was most conspicuous in females. Kyphosis is
also a feature of SOD1G93A (Azzouz et al., 1997), SOD1G37R (Filali
et al., 2011), and Tardbp targeted inactivation ALS mouse models
(Wu et al., 2012). Animals expressing the DAOR199W transgene
consistently had a lower body weight at each age compared
to wild type littermates (n = 15–23 per gender per genotype).
Kyphosis was not detected in any wild-type animals.
In order to determine whether the presence of the DAOR199W
mutation affected motor neuron populations, ventral hornmotor
neurons in the lumber region (L3-L5) of the spinal cord of
DAOR199W and control littermates were quantified at 14 months
(n ≥ 5 per genotype, per sex) and showed a significant reduction
of 19% (p< 0.023) inmotor neuron numbers inmice carrying the
mutant allele in comparison to their wild type littermates. When
separated according to gender, a significant decrease (25.7%)
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was found in females (p = 0.0132) but in males a smaller non-
significant reduction was obtained (16.5%).
It was also interesting to compare these findings with those
obtained by Sasabe et al. (2012) using a mouse line that was
homozygous for a naturally occurring mutation, DAOG181R
(Konno and Yasumura, 1983), that severely impairs DAO enzyme
activity. To obtain a homozygous line, ddY/DAO− was initially
backcrossed with C57BL/6J mice. In these animals, abnormal
reflexes characterized by retraction of hind limbs were evident,
as reported in the SOD1G93A mouse model of ALS, together with
a reduction in motor neuron number of 24% in DAO−/− in mice
at 8 months. By 15 months, axonal degeneration with muscle
atrophy was detected together with increased ubiquitination in
spinal cord. Suppression of DAO activity was also observed in
the reticulospinal tract, a pathway that plays an important role
in regulating motor neuron excitability in animal models of ALS
(Sasabe et al., 2012).
In summary, while a mutation can cause a lethal disease in
humans, no overt ALS phenotype was evident in mice expressing
DAOR199W. However, marked structural and abnormal motor
features were evident which were associated with a significant loss
of lumbar motor neurons.
Triggering a “human” phenotype in mouse models is not
always possible (e.g., absence of upper motor neuron signs in ALS
models, lack of neurodegeneration in a VAPB transgenic model
of ALS; Tudor et al., 2010). Hence we used another approach and
investigated whether the DAOR199W mutation would potentiate
the effects of the SOD1 mouse model of ALS.
Does the Presence of DAOR199W Potentiate
the Effect of the SOD1G93A Mutation on
Motor Function and Survival?
To investigate the effect of overexpression of DAOR199W on
the development of the ALS-like phenotype and survival in the
SOD1G93A mouse model of ALS, these two lines were crossed
to generate four genotypes, controls lacking both transgenes,
SOD1G93A mice carrying a single transgene, DAOR199W mice
expressing a single transgene and double transgenic animals
(DAOR199W/SOD1G93A). A range of tests were performed
on each cohort, including weight measurement, onset of
neurological deficits, gait analysis and survival. The cohort size
for each cohort was >14 males and >14 females. Neurological
scores for both hind legs were assessed twice a week for
each mouse in a “blinded fashion” (scale of 0–4), developed
by ALSTDI. A significantly earlier onset of neurological signs
was seen in female SOD1G93A/DAOR199W females compared
to SOD1G93A females (p = 0.0239; Kondori et al., 2017). As
previously shown, significantly earlier onset of neurological signs
was found in SOD1G93A males compared to SOD1G93A females
(p= 0.0004).
In conclusion, these results suggest that impaired DAO
activity may increase D-serine levels and potentiate possible
excitotoxic effects mediated through the NMDA receptor. In
contrast enhanced levels of DAO may have beneficial effects.
This approach clearly has enormous potential for therapeutic
application to man in the treatment of both sporadic cases and
familial cases of ALS. Indeed the first drug licensed for treatment
of ALS, riluzole, which increases survival by 3–4 months but
does not confer long-term protection (Traynor et al., 2003) is
known to target glutamate release. However, a drug targeting
DAO would introduce an important degree of specificity in that
its effects would be focused on the D-serine/glycine binding site
of the NMDA receptor. Indeed, AAV administration of DAO in
SOD1G93A mice has now been shown to reduce motor neuron
loss. Overexpression of DAO in SOD1G93A mice was carried
out using a single injection of single stranded adeno-associated
virus serotype 9 (ssAAV9) vector (1 µl/g body weight (titre of
1012/ml) intrathecally into lumbar region at 90 days (Wang et al.,
2017), which alleviated motor neuron loss and glial activation
and extended survival. Although only moderate expression of
DAO was obtained, 2-fold compared to GFP vector injected and
non-transgenic controls, a significant beneficial effect could be
obtained in the combined cohort of males and females. When
split by gender this effect was only significant in females (p =
0.004).
Relevance of DAO to ALS Pathogenesis
This was also borne out in a recent comprehensive exome
sequencing study in 2,874 SALS cases and 6,405 controls, using
collapsing analysis where the gene acts as the unit of analysis. This
study identified TANK-binding kinase 1 (TBK1) as a new risk
gene for ALS. TBK1 is a kinase that phosphorylates Sequestosome
1 (SQSTM1) and Optineurin (OPTN), two components of
autophagy enabling autophagosome generation. Interestingly, in
addition, the authors showed that DAO was the only known
predisposition gene where the presence of DNA variants was
significantly associated with clinical outcome, decreasing rates of
survival (Cirulli et al., 2015).
A further link between key players in ALS pathogenesis,
namely, the RNA binding proteins (RBPs) and DAO has
also emerged recently. RBPs (TARDBP, FUS, TAF15) play an
important role in RNA processing and are strongly implicated
in ALS, as mutations in these genes cause FALS. Recently, a
mutation in the RBP hnRNP A2/B2 (D290V) was identified
that, in common with mutations in the FALS gene VCP,
causes multisystem proteinopathy. hnRNP A2/B2 targets UAGG
motifs in 564 genes affecting RNA processing, splicing and
polyadenyation (targeting 3′UTR rather than introns). Both
the pathogenic mutation and knockdown of this gene led to
abnormal splicing changes (Martinez et al., 2016). Using splicing
microarray analysis, the most significant and robust alternative
splicing event seen after depletion of hnRNP A2/B1 was exon
9 skipping in DAO (a 118 nucleotide cassette). This short form
of DAO (DAO-short) lacks 2 alpha helices and 3 beta sheets
due to a reading frameshift and early truncation of the protein,
severely reducing enzyme activity. The effect of hnRNP A2B1
knockdown (ASO) on expression of the alternative splice (AS)
variant (short) was to cause an increase in AS mRNA but a
decrease in AS protein. Furthermore, stably expressing cell lines
for each isoform showed reduced protein levels in DAO-short
despite similar transcript levels of each isoform (Martinez et al.,
2016).
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In summary, depletion of hnRNP A2/B1 protein substantially
lowered the abundance of the longer (constitutive) transcript
compared to the shorter spliced isoform. In contrast to the
constitutive form, the shorter isoform of DAO exhibited reduced
enzymatic activity and reduced D-serine metabolism. Thus,
these effects of hnRNP A2/B1 knockdown on the regulation of
splicing of DAO are consistent with a potential DAO-mediated
mechanism of pathogenicity and the lower levels of hnRNP
A2/B1 observed in ALS. Overall these findings are of considerable
importance as they highlight a potent regulatory mechanism
that could underpin the neurodegenerative process through
the switch between transcripts yielding stable proteins to those
yielding unstable proteins subject to rapid degradation.
CONCLUSION
From the data presented in this mini-review, it can be seen
from a wide range of experimental approaches that evidence
is accumulating for an important role of DAO in ALS.
Studies carried out both in cell culture and in vivo show that
expression of DAO carrying a mutation associated with FALS
causes a range of pathological features characteristic of ALS.
Furthermore, genetic analysis implicates a significant association
between the abundance of DAO variants and ALS severity.
In addition, the regulatory effects of the RNP, hnRNP A2/B1,
reported on DAO splicing, suggest a possible mechanism of ALS
pathogenesis.
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